{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:53:57Z","timestamp":1794322437484,"version":"4.9.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.heliyon.2023.e16367","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T11:36:04Z","timestamp":1684582564000},"page":"e16367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7519-7739","authenticated-orcid":false,"given":"Giovanni","family":"Antonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-3417","authenticated-orcid":false,"given":"Maurizio","family":"Inghilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Sgarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"deRuyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-7214","authenticated-orcid":false,"given":"Laura","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-6659","authenticated-orcid":false,"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e16367_bib1","series-title":"Myasthenia Gravis. StatPearls, Treasure Island (FL)","author":"Beloor Suresh","year":"2021"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e16367_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e16367_bib3","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.heliyon.2023.e16367_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual. Life Outcome"},{"issue":"3\u20134","key":"10.1016\/j.heliyon.2023.e16367_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000487886","article-title":"Epidemiology of myasthenia gravis in Slovakia in the years 1977-2015","volume":"50","author":"Martinka","year":"2018","journal-title":"Neuroepidemiology"},{"issue":"20","key":"10.1016\/j.heliyon.2023.e16367_bib6","first-page":"30215","article-title":"Epidemiology of myasthenia gravis in the province of Ourense (Galicia, Spain). Epidemiolog\u00eda de la miastenia gravis en la provincia de Ourense (Galicia, noroeste de Espa\u00f1a)","volume":"S0213\u20134853","author":"Garc\u00eda Est\u00e9vez","year":"2020","journal-title":"Neurologia"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e16367_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1819","article-title":"Epidemiology of myasthenia gravis in Sweden 2006-2016","volume":"10","author":"Westerberg","year":"2020","journal-title":"Brain Behav."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16367_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ene.13535","article-title":"A nationwide epidemiological study of myasthenia gravis in Latvia","volume":"25","author":"Zieda","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e16367_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261983","article-title":"Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: a retrospective study using primary care data","volume":"16","author":"Carey","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e16367_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol. Sci. : Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.heliyon.2023.e16367_bib11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16367_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12028-021-01259-4","article-title":"Acetylcholinesterase inhibitors in myasthenic crisis: a systematic review of observational studies","volume":"35","author":"Prado","year":"2021","journal-title":"Neurocr. Care"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16367_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.heliyon.2023.e16367_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.605902","article-title":"Controversies in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16367_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.heliyon.2023.e16367_bib16","unstructured":"https:\/\/www.gazzettaufficiale.it\/eli\/id\/2022\/09\/08\/22A05103\/SG."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e16367_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16367_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e16367_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048198","article-title":"Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG)","volume":"11","author":"Berrih-Aknin","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2023.e16367_bib20","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1016\/j.jval.2020.04.996","article-title":"PND105 the economic and quality of life burden that myasthenia gravis has on patients: a us targeted literature review","volume":"23","author":"Silvestri","year":"2020","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e16367_bib21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chron. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e16367_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000109688","article-title":"Epidemiology of myasthenia gravis in northwestern Sardinia","volume":"16","author":"Aiello","year":"1997","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16367_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000110923","article-title":"Epidemiology of myasthenia gravis in the province of Trento (northern Italy)","volume":"11","author":"Ferrari","year":"1992","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16367_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000336002","article-title":"Epidemiology and geographical variation of myasthenia gravis in the province of Pavia","volume":"38","author":"Montomoli","year":"2012","journal-title":"Italy. Neuroepidemiology"},{"key":"10.1016\/j.heliyon.2023.e16367_bib25","unstructured":"I miastenici in Italia. Miastenia n.d. Available from: https:\/\/www.miastenia.it\/la-miastenia\/i-miastenici-in-italia\/(last accessed April 14, 2023)."},{"key":"10.1016\/j.heliyon.2023.e16367_bib26","unstructured":"La Miastenia \u2013 Vivere la Miastenia n.d. Available from: https:\/\/www.viverelamiastenia.it\/la-miastenia\/(last accessed April 14, 2023)."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16367_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70539-4","article-title":"Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis","volume":"10","author":"D\u00edez-Porras","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16367_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids","volume":"30","author":"Tannemaat","year":"2020","journal-title":"Neuromuscul. Disord.: NMD"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e16367_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00804-2019","article-title":"Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study","volume":"54","author":"Lee","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e16367_bib30","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/ene.12439","article-title":"Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study","volume":"21","author":"Andersen","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e16367_bib31","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16367_bib32","first-page":"36","article-title":"Progress in the treatment of myasthenia gravis","volume":"1","author":"Gold","year":"2008","journal-title":"Therap. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16367_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/2576117X.2021.1904097","article-title":"Quantification of cover test prior and post pyridostigmine in diagnosis of myasthenia gravis","volume":"71","author":"Saint-Gerons","year":"2021","journal-title":"J. Binocular Vis. Ocular Motil."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023035740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023035740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:47:08Z","timestamp":1790470028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023035740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2405844023035740"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e16367"}}